about
Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trialsPolymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenImpact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patientsA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityFactors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsEvaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data.Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesScoring methods for building genotypic scores: an application to didanosine resistance in a large derivation setPredictive capability of proportional hazards regression.Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population.Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to MaravirocComparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal ApproachComparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirOn the use of auxiliary data to estimate the survival function and its variance: an application to acquired immunodeficiency syndrome.Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patientsGenotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.Impact of pre-therapy viral load on virological response to modern first-line HAART.Accuracy of predictive ability measures for survival models.Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.Choice of effect measure in HIV randomized trials.Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.
P50
Q28476822-88B6601B-73F2-4315-B31E-17C0DD8AB142Q28477151-F71A12C5-73B4-4393-B7FE-87D5450F2CB7Q28483630-049637AD-2906-4280-903E-9FFDC7207165Q28533996-D7AB64F0-401E-4F05-B993-43B651D21E73Q33558937-0E9AB5A0-AB63-44EE-B4DC-3383CD9BA2A4Q34045403-8DDC588B-335A-46C6-83CB-D77A9177F81EQ34253401-E55E286E-521C-4925-B8D7-9589C9FD76DEQ34563005-1AFCA824-8869-4B4F-B5F7-497961AF5E47Q34650691-45368AEE-86FC-4026-A0F9-6B42AA35C035Q35106281-10F3622F-CD8C-4361-92F7-F67CAC9D3C12Q35249747-63704A3C-01D2-4890-ADE4-1D7387B328AFQ35542299-35D8CC46-24B3-493B-9D69-4CB17EC33ED1Q35662019-78C89958-D955-4997-B30C-BDF48C574D87Q36195887-1137628B-4E07-4897-85FB-A79AE0A5FD59Q36250342-143F531A-6111-4568-A141-DFE35DD5383EQ36424925-1A949AAB-22B8-447A-9FAF-E1CEE911DA59Q36806923-82ABCE87-F4F1-4780-897B-8544244E934AQ36870850-7C02F880-FB38-43B2-8DD1-917C3BE838F7Q36993465-1159BCF0-79A0-4EF3-8994-989AE077DB45Q38380110-453E4074-7762-4F27-A56B-D41DC13176C1Q38427973-F0C3FDD1-8B5A-40A6-99B0-B4D57B854FACQ38739064-C7D95D8C-E99C-47E2-8B50-45CB80803107Q39005718-058AC699-C725-403E-82FF-A3B7CE36CBC8Q39016016-305DA041-8E33-4F33-B953-5C2470ED70FCQ39321798-E493595F-8B73-404C-BE37-08FA0130307FQ39480583-1CDE54C7-7E33-4FA5-A835-7A65F1806995Q39526764-ED856718-B6A3-4942-B37A-6D9CC7D7557BQ39843128-5264D265-00FB-4CD7-BAB3-D42E0F2EC5F3Q40215147-3A1044D8-640B-4DF8-86BC-9AD9CC836556Q40786383-310F669F-FC6F-4768-86F4-E0BA3378310EQ40812700-4A9FCC34-D989-4AC8-93C5-80E4434D8E21Q41007320-CADC98FD-8F81-4010-B7AC-806D1DF307E0Q41564156-128F9EF6-E9C8-4E63-A038-86170F2FC59FQ41688961-F8178FB4-55C8-4D5A-96A3-7095764D7043Q42251326-787CF9AF-4F80-4BA8-864B-BA4964B851E9Q42375999-BA0DD122-B64B-49A6-BF23-F1CCAB45BFCBQ42685014-45EA2067-460E-4E9B-ADAB-7D048EB92E0FQ42929822-3DD0F46F-4CA5-4D2B-BE85-39064DCFA7A0Q43102710-8D030B16-7D9F-467D-BFD3-8949453FBC38Q43124622-57EEBD3C-DEAF-4679-A063-A26C02BF4755
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philippe Flandre
@ast
Philippe Flandre
@en
Philippe Flandre
@es
Philippe Flandre
@nl
Philippe Flandre
@sl
type
label
Philippe Flandre
@ast
Philippe Flandre
@en
Philippe Flandre
@es
Philippe Flandre
@nl
Philippe Flandre
@sl
prefLabel
Philippe Flandre
@ast
Philippe Flandre
@en
Philippe Flandre
@es
Philippe Flandre
@nl
Philippe Flandre
@sl
P1053
N-6314-2017
P106
P21
P31
P3829
P496
0000-0002-2612-3522
P569
2000-01-01T00:00:00Z